F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comLincoln Pharmaceuticals Ltd, a leading name in the Indian pharmaceutical sector, is known for its strong product portfolio in therapeutic areas such as anti-infectives, anti-malarials, anti-psychotics, cardiovascular, gastrointestinal, and pain management. The company has consistently grown with a focus on affordable healthcare solutions, exports, and research-driven product development.
In this article, we’ll analyze Lincoln Pharmaceuticals’ business model, current financial performance, and share price target forecast from 2025 to 2030.
| Detail | Value |
|---|---|
| Current Price | ₹549.00 |
| Previous Close | ₹548.25 |
| Day’s High | ₹553.85 |
| Day’s Low | ₹545.00 |
| 52-Week High | ₹979.50 |
| 52-Week Low | ₹499.00 |
| Market Capitalization | ₹1,103 Cr |
| Beta (Volatility) | 1.14 |
| Book Value Per Share | ₹319.16 |
| Face Value | ₹10 |
| Dividend Yield | 0.33% |
| All-Time High | ₹979.50 |
| All-Time Low | ₹85.05 |
Founded in 1979, Lincoln Pharmaceuticals Ltd is headquartered in Ahmedabad, Gujarat. It manufactures and markets branded generics, APIs (Active Pharmaceutical Ingredients), and specialty formulations across India and over 60 international markets.
Strong presence in African, Latin American, and South-East Asian markets.
Wide product portfolio across cardiology, psychiatry, and infectious disease categories.
R&D-driven company with approvals from WHO-GMP, EU-GMP, and various regulatory bodies.
Growing export base contributing a significant portion of revenue.
Consistent focus on affordable healthcare and product innovation.
| Investor Type | Holding (%) |
|---|---|
| Promoters | 49.78% |
| Foreign Institutions | 5.14% |
| Other Domestic Institutions | 0.01% |
| Retail & Others | 45.07% |
This shareholding pattern shows strong promoter confidence along with substantial retail participation.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 560 | 590 |
| 2026 | 600 | 650 |
| 2027 | 670 | 720 |
| 2028 | 750 | 820 |
| 2029 | 850 | 930 |
| 2030 | 950 | 1,050 |
These projections are based on Lincoln Pharmaceuticals’ market presence, product launches, EPS growth, and the expanding global pharmaceutical demand.
In 2025, Lincoln’s share price is expected to stay steady with slight upward momentum.
Why?
Stable domestic sales.
Growing exports in Africa and Asia.
Solid demand for branded generics.
Investment Advice: Suitable for long-term investors; accumulate on dips.
By 2026, expansion in regulated markets could boost valuations.
Why?
Increased exports to the US and EU markets.
Strong R&D pipeline.
Improved operating margins.
Investment Advice: Hold for medium- to long-term gains.
2027 may witness robust growth as Lincoln strengthens its global footprint.
Why?
New product approvals.
Entry into newer geographies.
Enhanced EPS performance.
Investment Advice: Investors can reinvest dividends; potential CAGR looks promising.
Lincoln’s growth story continues with a focus on specialty formulations.
Why?
Higher demand for affordable generic drugs.
Efficient supply chain in global markets.
Strong promoter holding ensuring stability.
Investment Advice: Long-term holding recommended.
By 2029, Lincoln may cross ₹900 levels if demand momentum continues.
Why?
Strong financial performance.
Better market positioning in exports.
Improved EBITDA margins.
Investment Advice: Good stock for mid- and long-term portfolios.
By 2030, Lincoln could potentially reclaim its all-time high levels.
Why?
Expanding product portfolio in high-demand therapies.
Rising healthcare spending globally.
Strong brand recall in international markets.
Investment Advice: Excellent option for long-term investors seeking steady wealth creation.
Yes, Lincoln Pharmaceuticals Ltd can be considered a promising investment option due to:
Strong promoter confidence with nearly 50% holding.
Diverse product portfolio across therapeutic areas.
Export-driven growth in emerging and regulated markets.
Steady financial performance with strong book value and low debt.
Regulatory hurdles in international markets.
Fluctuating raw material costs.
Currency exchange risks due to export dependence.
Lincoln Pharmaceuticals Ltd, with its growing exports, innovation-driven product portfolio, and strong promoter backing, stands out as a reliable mid-cap pharma stock. With a current price of around ₹549, analysts expect the stock to touch ₹1,050 levels by 2030.
For long-term investors seeking exposure in the pharmaceutical sector, Lincoln Pharmaceuticals could be a strong addition to their portfolios.
1. What is the current share price of Lincoln Pharmaceuticals?
The share price is currently around ₹549 (as of August 2025).
2. What is the share price target of Lincoln Pharmaceuticals for 2025?
The target ranges between ₹560 – ₹590.
3. Can Lincoln Pharmaceuticals reach ₹1,000 by 2030?
Yes, if export growth and R&D investments continue, it may cross ₹1,000.
4. Is Lincoln Pharmaceuticals a good long-term investment?
Yes, due to strong promoter holding, diversified product portfolio, and export-led growth.
5. What are the major risks in investing in Lincoln Pharmaceuticals?
Regulatory challenges, raw material price fluctuations, and forex risks.
???? Disclaimer: This article is for educational purposes only. Please consult a SEBI-registered financial advisor before making investment decisions.
Register & Login